Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 as a diagnostic marker for acute ST-elevation myocardial infarction

Abstract

Introduction: ST-elevation myocardial infarction (STEMI) is a major cause of mortality and morbidity worldwide, but fast and reliable diagnosis can reduce mortality. Therefore, this study aimed to assess the diagnostic value of serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) among patients with acute STEMI, and also its importance to monitor the response to percutaneous coronary intervention (PCI). A total of 30 healthy subjects and 150 acute STEMI patients treated by PCI were enrolled into our study. Besides the routine lab work, serum sLOX-1 level was measured using a commercial ELISA kit. Results: Our results revealed the increased serum sLOX-1 level among patients with acute STEMI (112.79 ± 10.76) than controls (47.75 ± 12.87). After the treatment of acute STEMI patients with the primary PCI, the level of serum sLOX-1 was not sigificantly decreased either after 12 hrs (111.04 ± 11.06) or 48 hrs (110.31 ± 11.24) from PCI management. Our results also showed that serum sLOX-1 level was positively correlated with cholesterol, LDL, troponin I, CK-MB, CRP, TG, and VLDL. Results obtained from ROC curve analysis showed that serum sLOX-1 is an excellent biomarker for acute STEMI disease, its AUC is one with 100% sensitivity and specificity. Conclusions: Finally, from these results, we can conclude that LOX-1 has a crucial role in the pathogenesis of acute STEMI; also, serum sLOX-1 could be a good diagnostic clinical biomarker for the detection of acute STEMI disease and to monitor the response to PCI.